Update on the Role of Ceftazidime-Avibactam in the Management of Carbapenemase-Producing Enterobacterales

References

• Hawkey PM . Multidrug-resistant Gram-negative bacteria: a product of globalization. J. Hosp. Infect.89(4), 241–247 (2015).
   PubMed Web of Science ®Google Scholar
• Canton R , AkovaM, CarmeliYet al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect.18(5), 413–431 (2012).
   PubMed Web of Science ®Google Scholar
• Logan LK , WeinsteinRA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J. Infect. Dis.215(Suppl. 1), S28–S36 (2017).
   PubMedGoogle Scholar
• Pitout JDD , LauplandKB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis.8(3), 159–166 (2008).
   PubMed Web of Science ®Google Scholar
• Cassini A , HögbergLD, PlachourasDet al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect. Dis.19(1), 56–66 (2019).
   PubMed Web of Science ®Google Scholar
• World Health Organization (2018). https://www.ecdc.europa.eu/sites/default/files/documents/Antimicrobial-consumption-EU-EEA.pdf
   Google Scholar
• Ehmann DE , JahicH, RossPLet al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc. Natl Acad. Sci. USA109(29), 11663–11668 (2012).
   PubMed Web of Science ®Google Scholar
• Zavicefta EPAR public assessment report. https://www.ema.europa.eu/en/medicines/uman/epar/zavicefta
   Google Scholar
• Vazquez JA , GonzalezPatzan LD, StricklinDet al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin.28(12), 1921–1931 (2012).
   PubMed Web of Science ®Google Scholar
• Van Duin D , BonomoRA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation beta-Lactam/beta-Lactamase Inhibitor Combinations. Clin. Infect. Dis.63(2), 234–241 (2016).
   PubMed Web of Science ®Google Scholar
• Merdjan H , RangarajuM, TarralA. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin. Drug Investig.35(5), 307–317 (2015).
   PubMed Web of Science ®Google Scholar
• Nicolau DP , SiewL, ArmstrongJet al. Phase I study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J. Antimicrob. Chemother.70(10), 2862–2869 (2015).
   PubMed Web of Science ®Google Scholar
• Lodise TP , NauR, KinzigM, DrusanoGL, JonesRN, SorgelF. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J. Antimicrob. Chemother.60(5), 1038–1044 (2007).
   PubMed Web of Science ®Google Scholar
• Zasowski EJ , RybakJM, RybakMJ. The beta-lactams strike back: ceftazidime-avibactam. Pharmacotherapy35(8), 755–770 (2015).
   PubMed Web of Science ®Google Scholar
• Lucasti C , PopescuI, RameshMK, LipkaJ, SableC. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J. Antimicrob. Chemother.68(5), 1183–1192 (2013).
   PubMed Web of Science ®Google Scholar
• Merdjan H , TarralA, DasS, LiJ. Phase I study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J. Clin. Pharmacol.57(2), 211–218 (2017).
   PubMed Web of Science ®Google Scholar
• Li J , ZhouD, DasS, LovernM, WadaR, BellantiF. PK/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia. Am. Assoc. Pharm. Sci. (AAPS) Anual Meeting and Exposition (2015).
   Google Scholar
• Torres A , ZhongN, PachlJet al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, Phase III non-inferiority trial. Lancet Infect. Dis.18(3), 285–295 (2018).
   PubMed Web of Science ®Google Scholar
• Wenzler E , BunnellKL, BleasdaleSC, BenkenS, DanzigerLH, RodvoldKA. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically Ill patient on continuous venovenous hemofiltration. Antimicrob. Agents Chemother.61(7), e00464–17 (2017).
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM , SobelJD, NewellPet al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase III randomized trial program. Clin. Infect. Dis.63(6), 754–762 (2016).
   PubMed Web of Science ®Google Scholar
• Carmeli Y , ArmstrongJ, LaudPJet al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, Phase III study. Lancet Infect. Dis.16(6), 661–673 (2016).
   PubMed Web of Science ®Google Scholar
• Mazuski JE , GasinkLB, ArmstrongJet al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, Phase III program. Clin. Infect. Dis.62(11), 1380–1389 (2016).
   PubMed Web of Science ®Google Scholar
• Qin X , TranBG, KimMJet al. A randomised, double-blind, Phase III study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int. J. Antimicrob. Agents49(5), 579–588 (2017).
   PubMed Web of Science ®Google Scholar
• Krapp F , GrantJL, SuttonSH, OzerEA, BarrVO. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Int. J. Antimicrob. Agents49(6), 770–773 (2017).
   PubMed Web of Science ®Google Scholar
• Shields RK , PotoskiBA, HaidarGet al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae Infections. Clin. Infect. Dis.63(12), 1615–1618 (2016).
   PubMed Web of Science ®Google Scholar
• Temkin E , Torre-CisnerosJ, BeovicBet al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob. Agents Chemother.61(2), e01964–16 (2017).
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ , TrinhTD, ZasowskiEJet al. Real-world experience with ceftazidime-avibactam for multidrug-resistant Gram-negative bacterial infections. Open Forum Infect. Dis.6(12), ofz522 (2019).
   PubMed Web of Science ®Google Scholar
• Sousa A , Perez-RodriguezMT, SotoAet al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J. Antimicrob. Chemother.73(11), 3170–3175 (2018).
   PubMed Web of Science ®Google Scholar
• De La Calle C , RodriguezO, MorataLet al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int. J. Antimicrob. Agents53(4), 520–524 (2019).
   PubMed Web of Science ®Google Scholar
• Shields RK , NguyenMH, ChenLet al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae Bacteremia. Antimicrob. Agents Chemother.61(8), e00883–17 (2017).
   PubMed Web of Science ®Google Scholar
• Van Duin D , LokJJ, EarleyMet al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin. Infect. Dis.66(2), 163–171 (2018).
   PubMed Web of Science ®Google Scholar
• Tumbarello M , TrecarichiEM, CoronaAet al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin. Infect. Dis.68(3), 355–364 (2019).
   PubMed Web of Science ®Google Scholar
• Tsolaki V , MantzarlisK, MpakalisAet al. Ceftazidime-avibactam to treat life-threatening infections from carbapenem resistant pathogens in critically ill mechanically ventilated patients. Antimicrob. Agents Chemother. doi:10.1128/AAC.02320-19 (2019) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Caston JJ , Lacort-PeraltaI, Martin-DavilaPet al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int. J. Infect. Dis.59, 118–123 (2017).
   PubMed Web of Science ®Google Scholar
• Pogue JM , BonomoRA, KayeKS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations. Clin. Infect. Dis.68(3), 519–524 (2019).
   PubMed Web of Science ®Google Scholar
• Lomovskaya O , CastanheiraM, VázquezJ, KayeK, NelsonK, SunD. Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGOII (a Phase III study of the treatment of CRE infections). ID Week (2017).
   Google Scholar
• Shields RK , NguyenMH, ChenL, PressEG, KreiswirthBN, ClancyCJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob. Agents Chemother.62(5), e02497–17 (2018).
   PubMed Web of Science ®Google Scholar
• Gaibani P , ReMC, CampoliC, VialePL, AmbrettiS. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization. Clin. Microbiol. Infect. doi:10.1016/j.cmi.2019.11.011 (2019) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Li J , LovernM, GreenMLet al. Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups. Clin. Transl. Sci.12(2), 151–163 (2019).
   PubMed Web of Science ®Google Scholar
• Das S , LiJ, RiccobeneTet al. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob. Agents Chemother.63(4), e02187–18 (2019).
   PubMed Web of Science ®Google Scholar
• Sy SKB , ZhuangL, SyS, DerendorfH. Clinical pharmacokinetics and pharmacodynamics of ceftazidime-avibactam combination: a model-informed strategy for its clinical development. Clin. Pharmacokinet.58(5), 545–564 (2019).
   PubMed Web of Science ®Google Scholar
• Neuner EA , GallagherJC. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence8(4), 440–452 (2017).
   PubMed Web of Science ®Google Scholar
• Roberts JA , PaulSK, AkovaMet al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin. Infect. Dis. 58(8), 1072–1083 (2014).
   PubMed Web of Science ®Google Scholar
• Krueger WA , BulittaJ, Kinzig-SchippersMet al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother.49(5), 1881–1889 (2005).
   PubMed Web of Science ®Google Scholar
• Lal A , JaoudeP, El-SolhAA. Prolonged versus intermittent infusion of beta-lactams for the treatment of nosocomial pneumonia: a meta-analysis. Infect. Chemother.48(2), 81–90 (2016).
   PubMed Web of Science ®Google Scholar
• Macvane SH , KutiJL, NicolauDP. Prolonging beta-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int. J. Antimicrob. Agents43(2), 105–113 (2014).
   PubMed Web of Science ®Google Scholar
• Jacobs DM , DitursiS, RuhCet al. Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient. Int. J. Antimicrob. Agents48(2), 225–227 (2016).
   PubMed Web of Science ®Google Scholar
• Muller AE , PuntN, MoutonJW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J. Antimicrob. Chemother.68(4), 900–906 (2013).
   PubMed Web of Science ®Google Scholar
• Mckinnon PS , PaladinoJA, SchentagJJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int. J. Antimicrob. Agents31(4), 345–351 (2008).
   PubMed Web of Science ®Google Scholar
• Machuca I , Gutierrez-GutierrezB, PerezCortes Set al. Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae. J. Antimicrob. Chemother.71(11), 3242–3249 (2016).
   PubMed Web of Science ®Google Scholar
• Tascini C , SbranaF, FlamminiSet al. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob. Agents Chemother.58(4), 1972–1976 (2014).
   PubMed Web of Science ®Google Scholar
• Bassetti M , CarannanteN, PallottoCet al. KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: a retrospective observational study. J. Glob. Antimicrob. Resist.17, 109–111 (2019).
   PubMed Web of Science ®Google Scholar